Reports of cases detail the development of thyroid eye disease 3-5 years following treatment of MS with immunomodulatory ...

Patients with thyroid eye disease, a condition that causes the eyes to bulge forward due to swelling behind the eyeball, now ...

The U.S. Food and Drug Administration has approved Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED).

Thyroid eye disease (TED) is an inflammatory condition affecting those with thyroid disease. There is no cure, but effective management strategies exist. Thyroid eye disease, or Graves’ ophthalmopathy ...

The U.S. Food and Drug Administration on Friday approved Viridian Therapeutics Inc.’s VRDN new thyroid eye disease (TED) ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Thyroid eye disease (TED), also known as Graves’ eye disease, usually stems from an autoimmune condition that starts when immune cells attack the thyroid gland, a tiny butterfly-shaped gland at the ...

Because thyroid eye disease is a complex and multisystemic condition, a group of specialists often work together in its diagnosis and management. This often includes an ophthalmologist, an ...

Annie Larsson, 40, is no stranger to chronic conditions. She was diagnosed with type 1 diabetes at a young age and had it “completely managed” for years. Then, right before the Covid pandemic began, ...

Viridian Therapeutics said the U.S. Food and Drug Administration has approved Lumvoa to treat thyroid eye disease. The company said it will launch Lumvoa immediately, adding physicians can begin ...

As mentioned in Overview, most thyroid eye disease (TED) cases are closely related to hyperthyroidism. Approximately 85% of patients with TED develop the disease around 18 months before or after the ...